Nebenwirkungen · Ferriprox
Ferriprox 500 mg film-coated tablets Ferriprox 1 000 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-089837 · Präparat HOS-083927
The most serious adverse reaction reported in clinical studies with deferiprone is agranulocytosis (neutrophils < 0.5x109/l), with an incidence of 1.1% (0.6 cases per 100 patient-years of treatment) (see section 4.4). Data from pooled clinical studies in patients with systemic iron overload showed that 63% of the episodes of agranulocytosis occurred within the first six months of treatment, 74% within the first year and 26% after one year of therapy. The median time to onset of the first episode of agranulocytosis was 190 days (ranged 22 days- 17.6 years) and median duration was 10 days in clinical studies. A fatal outcome was observed in 8.3% of the reported episodes of agranulocytosis from clinical studies and post-marketing experience.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-04-21T02:00:00Z · SHA-256 8d30ff208e2cac65daccef3e0bb072261a28975145087d11012d5a853f6fab1e · Passage ae646cd5b0f4238280e71b16912e15c33e4bd67aa2ef239f2ce83a25d4838922 · Zeichen 2212–2960 im Abschnitt